Experts: ACA changes to hurt consumers in 2018

Oct. 17, 2017—Consumers will be hurt by the Trump administration’s moves to change the Affordable Care Act (ACA), experts tell us. The only questions are by how much and whether that will change in the years ahead.

Medication first to aim at cancer biomarker

May 24, 2017—Food and Drug Administration approved the first medication that’s designed to treat cancer patients whose cancer has a specific genetic feature, or biomarker, rather than being based on the location where a tumor was found.

Second ALS treatment approved

May 8, 2017—Food and Drug Administration approved the first new medication for the treatment for amyotrophic lateral sclerosis (ALS), which is commonly known as Lou Gehrig’s disease, in 22 years.

FDA approves medication to treat MS

March 30, 2017—As expected, Food and Drug Administration approved ocrelizumab for the treatment of adults who have one of several forms of multiple sclerosis (MS).

Expected health-insurance changes unlikely to affect 2017

Nov. 10, 2016—Change will come to how some consumers buy health insurance—the recent presidential election all but guarantees it—but two experts tell Consumers Digest that any changes likely won’t take effect in 2017. In other words, consumers who are eligible to buy insurance through the Affordable Care Act (ACA) marketplace should act as though nothing has changed.

MyPillow to end health-related claims

Nov. 1, 2016—The makers of MyPillow bedding might be resting a little less easy after reaching a settlement with California over claims that the company violated false-advertising laws.

FDA bans 19 antibacterial-soap ingredients

Sept. 2, 2016—Food and Drug Administration approved a final rule that banned 19 active ingredients that are used in antibacterial soaps, because the soapmakers couldn’t back claims that the ingredients were safe and more effective than plain soap and water.

Combination tablet approved to treat chronic hepatitis C

June 30, 2016—Food and Drug Administration approved a medication to treat adults who have chronic hepatitis C. The medication also is approved in combination with ribavirin to treat patients who have moderate-to-severe cirrhosis (advanced liver disease).